We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amarin, FDA to Discuss Settlement Options Following Off-Label Ruling
Amarin, FDA to Discuss Settlement Options Following Off-Label Ruling
Amarin is asking a New York federal court judge to halt further litigation with the FDA over off-label promotion of its cholesterol-lowering drug Vascepa until Oct. 30, while the parties discuss possible settlement options.